These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 34219

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Present-day treatment of dyskinesias (author's transl)].
    Fonsegrive J.
    Sem Hop; ; 55(1-2):88-9. PubMed ID: 34220
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease].
    Kannari K, Kurahashi K, Tomiyama M, Maeda T, Arai A, Baba M, Suda T, Matsunaga M.
    No To Shinkei; 2002 Feb; 54(2):133-7. PubMed ID: 11889759
    [Abstract] [Full Text] [Related]

  • 6. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A, Trenkwalder C, Oehlwein C, Winkelmann J, Polzer U, Hundemer HP, Schwarz J.
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [Abstract] [Full Text] [Related]

  • 7. [Therapeutical approach to involuntary movements (author's transl)].
    Allain H, Sabouraud O.
    Sem Hop; 2005 Sep; 55(5-6):262-4. PubMed ID: 219537
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
    Lundblad M, Usiello A, Carta M, Håkansson K, Fisone G, Cenci MA.
    Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Dyskinesia caused by L-DOPA].
    Derkinderen P, Vidailhet M.
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F, Lilliu H, Le Pen C.
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 17. ["Beginning and end of dose" dyskinesias caused by L-DOPA].
    Lhermitte F, Agid Y, Signoret JL, Studler JM.
    Rev Neurol (Paris); 1977 May; 133(5):297-308. PubMed ID: 897439
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
    Buck K, Ferger B.
    Neuroscience; 2009 Mar 03; 159(1):16-20. PubMed ID: 19146929
    [Abstract] [Full Text] [Related]

  • 20. [Abnormal movements induced by L-dopa. New therapeutic possibilities].
    Eisenring J-J, Constantinidis J, Dick P, Yanniotis G, Tissot R.
    Schweiz Med Wochenschr; 1975 Jan 25; 105(4):121-4. PubMed ID: 1124379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.